It is made available under a CC-BY 4.0 International license .

Evaluation and Clinical Validation of Monkeypox Virus Real-Time PCR Assays

1

2	
3	Margaret G. Mills <sup>1*</sup> , Kate B. Juergens <sup>1*</sup> , Jolene Gov <sup>1</sup> , Carter McCormick <sup>1</sup> , Reigran Sampoleo <sup>1</sup> ,
4	Alisa Kachikis <sup>6</sup> , John K. Amory <sup>6</sup> , Ferric C. Fang <sup>ae</sup> , Ailyn C. Pérez-Osorio <sup>8</sup> , Nicole A. P.
5	Lieberman <sup>a</sup> , Alexander L. Greninger <sup>ad</sup> #
6	
7∙	<sup>a</sup> Department of Laboratory Medicine and Pathology, University of Washington School of
8	Medicine, Seattle, WA, 98195, USA.
9	<sup>b</sup> Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, 98195,
10	USA.
11	Department of Medicine, University of Washington, Seattle, WA, 98195, USA.
12•	<sup>a</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle,
13	WA, 98109, USA.
14•	
15	#Address correspondence to Alexander L. Greninger, agrening@uw.edu
16	*Authors contributed equally to this work.
17	
18	Abstract
19	BACKGROUND: In spring of 2022, an outbreak of monkeypox spread worldwide. Here, we
20	describe performance characteristics of monkeypox virus (MPXV)-specific and pan-
21	orthopoxvirus qPCR assays for clinical use.
22	METHODS: We validated probe-based qPCR assays targeting MPXV-specific loci F3L and
23	G2R (genes MPXVgp052/OPG065 and MPXVgp002 and gp190/OPG002, respectively) and a

24	pan-orthopoxvirus assay targeting the E9L locus (MPXVgp057/OPG071). Clinical samples and
25	synthetic controls were extracted using the Roche MP96 or Promega Maxwell 48 instrument.
26	qPCR was performed on the AB7500 thermocycler. Synthetic control DNA and high
27	concentration clinical samples were quantified by droplet PCR. Cross-reactivity was evaluated
28	for camelpox and cowpox genomic DNA, vaccinia culture supernatant, and HSV- and VZV-
29	positive clinical specimens. We also determined analytical performance of the F3L assay using
30	dry swabs, Aptima vaginal and rectal swabs, nasopharyngeal, rectal, and oral swabs,
31	cerebrospinal fluid, plasma, serum, whole blood, breastmilk, urine, saliva, and semen.
32	RESULTS: The MPXV-F3L assay is reproducible at a limit of detection (LoD) of 65.6
33	copies/mL of viral DNA in VTM/UTM, or 3.3 copies/PCR reaction. No cross-reactivity with
34	herpesviruses or other poxviruses was observed. MPXV-F3L detects MPXV DNA in alternative
35	specimen types, with an LoD ranging between 260-1000 copies/mL, or 5.7-10 copies/PCR
36	reaction. In clinical swab VTM specimens, MPXV-F3L and MPXV-G2R assays outperformed
37	OPXV-E9L by an average of 2.4 and 2.8 Cts, respectively. MPXV-G2R outperformed MPXV-
38	F3L by 0.4 Cts, consistent with presence of two copies of G2R present in labile inverted terminal
39	repeats (ITRs) of MPXV genome.
40	CONCLUSIONS: MPXV is readily detected by qPCR using three clinically validated assays.

- 41 Keywords
- 42 Monkeypox virus, qPCR, orthopox, F3L, G2R, alternative specimen

It is made available under a CC-BY 4.0 International license .

### 43 Introduction

44 Since its discovery in the 1970s, human cases of monkeypox (MPX) have rarely been reported 45 outside of countries in western and central Africa where the causative agent, monkeypox virus 46 (MPXV), is endemic (1). MPX is a zoonotic disease, and frequently causes isolated human 47 infections through spillover events (2). Despite evidence of increased human-to-human 48 transmission and warnings of global spread, the disease was largely neglected until its recent 49 emergence in an outbreak beginning in spring of 2022 (3–5). By November 2022, the epidemic 50 had expanded to over 77,000 cases detected in more than 100 countries worldwide. In the United 51 States, at time of writing, more than 28,000 cases have been reported, as well as several deaths 52 (6). Worldwide, this outbreak of human monkeypox has disproportionately burdened men who 53 have sex with men (7).

54 Individuals who contract MPXV may experience fever, lymphadenopathy, and a 55 disseminated papillary rash that can lead to secondary bacterial infections (8,9). Effects may 56 include significant pain for weeks, as well as a wide range of complications including 57 encephalitis, bronchopneumonia, and vision loss (10). Immunocompromised individuals, 58 particularly those with AIDS, are at high risk of severe manifestations of MPXV, including death 59 (11). Prophylactic vaccination with the JYNNEOS vaccinia virus vaccine and treatment with the 60 antiviral tecovirimat (Tpoxx), both originally developed for variola (smallpox), are the major 61 medical countermeasures available for MPXV. Because prevention of MPXV spread and 62 effective treatment of MPXV infection inherently rely on rapid and early detection, development of clinical quantitative PCR (qPCR) assays is critical for patient care and to disrupt networks of 63 64 transmission. In the context of a developing outbreak of an emerging virus that can be shed in

It is made available under a CC-BY 4.0 International license .

multiple body fluids, evaluation of assay performance in many alternative specimen types is also
critical to preparedness efforts (12, 13).

67	MPXV is a member of the orthopoxvirus (OPXV) family of double-stranded DNA
68	viruses. Although they are large (100-300 kb), OPXV genomes are highly conserved across
69	species, making MPXV-specific qPCR assay design a challenge. We evaluated two MPXV-
70	specific qPCR assays that target the F3L and G2R loci, and compared the sensitivity, specificity,
71	and accuracy of these assays to the CDC pan-orthpoxvirus assay OPXV-E9L (14-16). We also
72	assessed performance of all three assays in the presence of alphaherpesviruses. We found
73	MPXV-F3L and MPXV-G2R assays to have equivalent analytical sensitivity, with $100\%$
74	sensitivity at the limit of detection (LoD) of 65.6 copies/mL. OPXV-E9L had a sensitivity of
75	95% at the same LoD. We demonstrated that the MPXV-F3L assay does not cross react with
76	Camelpox virus (CMLV), Cowpox virus (CPXV) or Vaccinia virus (VACV) and detects MPXV
77	DNA with adequate sensitivity in fourteen different specimen types.
78	
79	Materials and Methods
80	Ethics and regulatory approvals
81	Use of excess clinical specimens was approved by the University of Washington Institutional

82 Review Board with a consent waiver (STUDY00010205). Specifically, the use of excess breast

- 83 milk and semen were approved as part of UW IRB-approved studies with informed consent
- 84 (STUDY00000853, STUDY00001055, STUDY00008491).

85

86 Primers and Probes

- 87 Primers and probes targeting the loci for MPXV-F3L (15), MPXV-G2R (14), and OPXV-E9L
- 88 (16) were synthesized by ThermoFisher. Sequences used were as follows: F3L forward 5'-
- 89 CATCTATTATAGCATCAGCATCAGA-3' and reverse 5'-
- 90 GATACTCCTCCTCGTTGGTCTAC -3', probe 5'-
- 91 FAM/TGTAGGCCGTGTATCAGCATCCATT/BHQ1-3'. G2R forward 5'-
- 92 GGAAAATGTAAAGACAACGAATACAG-3' and reverse 5'-
- 93 GCTATCACATAATCTGGAAGCGTA-3', probe 5'-
- 94 FAM/AAGCCGTAATCTATGTTGTCTATCGTGTCC/BHQ1-3'. E9L
- 95 forward 5'-TCAACTGAAAAGGCCATCTATGA-3' and reverse 5'-
- 96 GAGTATAGAGCACTATTTCTAAATCCCA-3', probe 5'-
- 97 VIC/CCATGCAATATACGTACAAGATAGTAGCCAAC/QSY-3'.
- 98
- 99 MPXV DNA Absolute Quantification With ddPCR
- 100 Absolute quantities of standards used to create contrived MPXV-positive samples were
- 101 determined using droplet digital PCR (ddPCR). Each ddPCR reaction was performed in
- 102 quadruplicate and included 1.25µL water, 12.5µL ddPCR Mastermix for Probes (Bio-Rad),
- 103 1.25µL of 20x primer/probe mix (900 nM primers, 250 nM probe), and 10µL template DNA.
- 104 Following droplet generation, amplification on the Bio-Rad C1000 Touch ddPCR system
- 105 consisted of 10 min at 95°C; 40 cycles of 30 sec at 94°C, one min at 60°C; and 10 min at 98°C.
- 106 Amplification was detected using QX200 Droplet Reader (Bio-Rad) and results analyzed with
- 107 QuantaSoft Pro v1.0.596 software (Bio-Rad) (17).
- 108
- 109 Nucleic Acid Extraction

It is made available under a CC-BY 4.0 International license .

110	All samples were handled in a biosafety cabinet prior to viral inactivation. DNA from breastmilk
111	and semen specimens was extracted on the Promega Maxwell 48 with Maxwell RSC Viral Total
112	Nucleic Acid Purification Kit. Breastmilk specimens were spun down for 10 minutes to separate
113	the fat layer, and the liquid was used for extraction. Two hundred twenty microliters of sample
114	were mixed with 200 $\mu$ L extraction mix (181.5 $\mu$ L lysis buffer, 18.2 $\mu$ L proteinase K, and 0.38 $\mu$ L
115	EXOBS internal control). Samples were then incubated for 10 min at room temperature and 10
116	min at 56°C, then extracted following manufacturer protocols and eluted in 100 $\mu$ L of Promega
117	elution buffer.
118	DNA from all other specimen types was extracted on the MagNA Pure 96 with the DNA
119	and Viral NA Small Volume Kit unless otherwise noted. Aptima collection tubes contain a
120	reagent to inactivate MPXV, so 200µL from these tubes was extracted without additional lysis
121	buffer. For lesion, nasopharyngeal, rectal, or oral swabs in viral transport media or universal
122	transport media (VTM/UTM), cerebrospinal fluid (CSF), plasma, serum, whole blood, urine, or
123	saliva, 100µL of sample was added to 100µL of buffer AL (Qiagen). Dry swabs were added to 1
124	mL VTM/UTM, incubated for 1 min, vortexed for 10 seconds, and treated as above. All samples
125	were eluted in 100µL Roche elution buffer.
126	Select specimens were extracted on the MagNA Pure 96 with the DNA and Viral NA
127	Large Volume Kit, with 250 $\mu$ L of sample added to 250 $\mu$ L of buffer AL (Qiagen), then eluted in
128	50µL Roche elution buffer.
129	
130	Qualitative PCR

131 All F3L and G2R qPCR reactions contained 2.71µL water, 11.95µL No-ROX QuantiTect master

132 mix (Qiagen), 0.55µL ROX QuantiTect master mix (Qiagen), 0.1µL each of 100µM assay-

133	specific forward and reverse primers, 0.05µL of 100µM assay-specific probe, 0.063µL EXOBS
134	internal control primer/probe mix (18), 0.025µL of Uracil-N-Glycosylase (0.025 units, EpiCentre
135	technologies), and 10µL of template DNA. All E9L qPCR reactions contained an additional
136	$0.063\mu$ L water in place of EXOBS primer/probe mix. Amplification on the 7500 Real-Time PCR
137	System (Applied Biosystems) consisted of 2 min at 50°C; 15 min at 95°C; and 45 cycles of 1
138	min at 94°C and 1 min at 60°C (17).
139	
140	Accuracy
141	Purified monkeypox DNA strain USA-2003 from BEI (NR-4928), and seven MPXV-positive
142	remnant clinical specimens identified by Washington State Public Health Lab (WA PHL) using
143	the OPXV-E9L primer/probe set, were used to establish accuracy (sensitivity) of the F3L and
144	G2R assays. Remnant skin swab samples in VTM/UTM that tested negative using the OPXV-
145	E9L assay were used to establish accuracy (specificity) of the F3L and G2R assays.
146	
147	Synthetic MPXV DNA from ATCC (VR-3270SD) and high-titer MPXV-positive remnant
148	clinical specimens identified by UWVL were used to spike into negative remnant clinical
149	specimens, resulting in contrived positive specimens to confirm accuracy (sensitivity) of the F3L
150	and G2R assays for all specimen types.
151	
152	Cross-Reactivity and Interfering Substances Analysis
153	To examine cross-reactivity of MPXV/OPXV assays with other orthopoxviruses, purified
154	camelpox (CMLV) and cowpox (CPXV) viral genomic DNAs were obtained from BEI
155	Resources (NR-50076 and NR-2641, respectively). Vaccinia virus culture supernatant (strain

It is made available under a CC-BY 4.0 International license .

- 156 NYCHB, a kind gift from Dr. David Koelle) was extracted as for swab specimens. All samples
- 157 were then assayed using the F3L, G2R, and E9L assays as described.
- 158 To test cross-reactivity of MPXV/OPXV assays with herpesviruses, 18 VZV-positive, 11
- 159 HSV1-positive, and four HSV2-positive skin swabs in VTM/UTM were selected from remnant
- 160 clinical specimens. The HSV-positive specimens represented a range of HSV assay Cts (17.2-
- 161 31.7). A subset of these VZV- and HSV-positive specimens were also spiked with VR-3270SD
- 162 to create contrived double MPXV/VZV- or MPXV/HSV-positive specimens. All samples
- 163 (MPXV-negative and -positive) were then assayed using the F3L, G2R, and E9L assays as
- 164 described.
- 165

#### 166 Analytical Sensitivity and Limits of Detection

167 Limits of detection for F3L and G2R assays were determined for contrived positive specimens

168 (synthetic DNA spiked into MPXV-negative remnant clinical specimens) in two stages. VR-

169 3270SD was first serially diluted 10-fold in four pooled MPXV-negative skin swabs in VTM,

170 with final concentrations of 3,300,000-33 copies/mL, and tested in 4 replicates per concentration.

171 Twenty replicates were then each were tested at 330 and 33 copies/mL. Extractions and qPCR

172 were performed as above.

Direct comparison of sensitivity/LoD for F3L, G2R, and E9L assays used a similar
procedure, but with extractions utilizing the MP96 DNA/Viral NA Large Volume extraction kit:
250µL of each sample were mixed with 250µL buffer AL, extracted, and eluted in 50 µL elution
buffer, representing a five-fold concentration. First, VR-3270SD was serially diluted in pooled
MPXV-negative skin swabs in VTM, 10-fold dilutions from 33,000-33 copies/mL then finer
dilutions between 330-33 copies/mL, and tested in 4 replicates per concentration. Second, 20

It is made available under a CC-BY 4.0 International license .

replicates each were tested at 330, 110, and 66 copies/mL. qPCR was performed as above witheach assay.

181

## 182 Analytical Sensitivity in Diverse Specimen Types

183 To test the specificity of the F3L assay in a variety of matrices, we gathered a total of 17-184 24 remnant clinical samples per specimen type. Nasopharyngeal, oral, and rectal swabs in 185 UTM/VTM, CSF, plasma, serum, whole blood, urine, and saliva, came from UW Virology 186 remnant clinical specimens. Semen and breastmilk were obtained from remnant clinical trial 187 specimens from the UW Medical Center. Vaginal and rectal swabs in Aptima multitest tubes 188 were obtained from Harborview Medical Center. All MPXV-negative specimens were extracted 189 and PCR-amplified with F3L as described above. 190 To test the analytical sensitivity in these specimen types and establish a rough LoD in 191 each, synthetic or viral MPXV DNA was spiked into n=20-24 samples per specimen type. VR-192 3270SD was spiked into CSF, plasma, serum, whole blood, nasopharyngeal swabs in 193 VTM/UTM, breastmilk, and urine to a final concentration of 1,000 copies/mL. Once MPXV-194 positive specimens were available, a high-titer clinical specimen was spiked into specimens: into 195 semen to a final concentration of 260 copies/mL; and into saliva, and oral and rectal swabs in 196 VTM/UTM to a final concentration of 780 copies/mL. All contrived positive specimens were 197 extracted and qPCR-amplified with F3L as described above. 198 Contrived positive dry swabs were made by diluting high-titer clinical specimen into 199 pooled negative swab specimens in VTM/UTM, adding 50µL to each swab, and air-drying for 200 10 min. Once the swabs were dry, each was added to 1mL VTM, incubated for 10 min, and

201 vortexed for 10 seconds. To establish an LoD for dry swabs, contrived positive samples were

It is made available under a CC-BY 4.0 International license .

202	made and tested in two stages. First, the high-titer clinical specimen was serially diluted 10-fold
203	to final concentrations of 5,300,000 - 530 copies/mL then finer dilutions between 5,300 - 530
204	copies/mL, and tested in 4 replicates per concentration. Second, 20 replicates each were tested at
205	1,600, 800, and 530 copies/mL (810, 400, and 270 copies/swab respectively). Dry swabs were
206	processed, extracted, and qPCR-amplified with F3L as described above.
207	
208	Results
209	Absolute quantification of synthetic control and high viral load clinical sample
210	Because MPXV genomic DNA and clinical samples were in short supply in spring 2022,
211	we first validated synthetic DNA purchased from ATCC (VR-3270SD). This template contains
212	primer and probe binding sites for several previously-developed assays, including F3L, G2R, and
213	E9L, and has a copy number of 1x10°-1x10° copies/mL DNA estimated by the manufacturer (14–
214	16). We determined the precise number of copies of this standard using ten-fold serial dilutions
215	tested in quadruplicate by ddPCR (Figure S1A-C). Measurements of VR-3270SD lot 70053297
216	yielded 3.28x10 <sup>s</sup> copies/mL DNA for F3L; measurements of VR-3270SD lot 70053666 resulted
217	in equivalent concentrations for all three loci: 1.28x10 <sup>s</sup> copies/mL for MPXV-F3L, 1.30x10 <sup>s</sup>
218	copies/mL for MPXV-G2R, and 1.29x10 <sup>s</sup> copies/mL for OPXV-E9L. In addition, a high viral
219	load remnant clinical specimen (F3L Ct $\sim$ 16) used for downstream validation studies was
220	quantified by ddPCR as 5.34x10 <sup>s</sup> , 8.78x10 <sup>s</sup> , and 4.78x10 <sup>s</sup> copies/mL for F3L, G2R, and E9L
221	respectively. These data are consistent with equal copy numbers of loci present in the ATCC
222	DNA standard and an extra copy of G2R present in MPXV genomes.
223	

224 MPXV-F3L and MPXV-G2R assays are highly specific for MPXV DNA

It is made available under a CC-BY 4.0 International license .

225	To determine specificity, we first tested 15 HSV-positive, 17 VZV-positive, and 52
226	known HSV/VZV-negative clinical remnant skin swabs in VTM/UTM using the CDC OPXV-
227	E9L assay and confirmed that they were negative for MPXV. We verified that the F3L assay did
228	not detect MPXV DNA in any of these specimens. The G2R assay similarly did not detect
229	MPXV DNA in the negative or HSV-positive swabs, or in 16 out of 17 VZV-positive swabs; one
230	VZV-positive specimen tested positive for G2R (Ct 39.8) and was negative on repeat (Table 1).
231	Overall, the F3L assay had a negative percent agreement of $100\%$ and the G2R assay had a
232	negative percent agreement of 98.8% over 84 samples.
233	Camelpox virus (CMLV), Cowpox virus (CPXV) and Vaccinia virus (VACV) are the
234	nearest phylogenetic relatives to MPXV based on DNA sequence similarity of conserved OPXV
235	genes (16, 19). Accordingly, we tested VACV viral culture and purified CMLV and CPXV
236	DNAs to assess cross-reactivity with MPXV-F3L and MPXV-G2R. The OPXV-E9L PCR assay
237	served as a positive control for the other OPXV. VACV, CPXV, and CMLV were not detected
238	by either the MPXV-F3L or MPXV-G2R assays, while the OPXV-E9L assay returned average
239	Cts of 23.8, 25.8, and 19.8, respectively (Figure 1A).
240	

# 241 Table 1: MPXV-F3L, MPXV-G2R, and OPXV-E9L Sensitivity and Specificity

F3L	Known (Contrived) Positive	Known Negative
Assay Positive	31	0
Assay Negative	1	84

242

G2R	Known (Contrived) Positive	Known Negative
Assay Positive	32	1

It is made available under a CC-BY 4.0 International license .

Assay Negative	0	83

243

E9L	Known (Contrived) Positive	Known Negative
Assay Positive	32	0
Assay Negative	0	84

244

245

### 246 MPXV-F3L, MPXV-G2R, and OPXV-E9L assays are > 96.8% sensitive for MPXV DNA

All three assays were tested for their ability to detect MPXV DNA using contrived

248 positives consisting of a range of dilutions of VR-3270SD spiked into negative skin swabs in

VTM (eight replicates at 330,000 copies/mL, 16 at 33,000 copies/mL, and eight at 3,300

250 copies/mL, based on ddPCR). G2R and E9L assays had 100% positive percent agreement, while

a single replicate at 3,300 copies/mL was negative in the F3L assay (G2R Ct = 36.6), resulting in

a positive percent agreement of 96.9%. Upon quadruplicate repeat testing, the failed sample had

F3L Cts of 32.2, 33.4, 32.9, and 33.0. Overall percent agreement for the three assays were 99.1%

for both G2R and F3L, and 100% for E9L.

255

### 256 MPXV-F3L and MPXV-G2R assays detect MPXV viral DNA

Next, we confirmed that the F3L and G2R assays would accurately identify samples
containing MPXV. Due to the short supply of MPXV-positive samples and genomic DNA early
in the 2022 MPXV pandemic, we were only able to secure MPXV genomic DNA from BEI
Resources, as well as seven MPXV-positive skin swabs in VTM from the WA State Public
Health Laboratory (PHL). All known positive samples tested positive for MPXV by both F3L

It is made available under a CC-BY 4.0 International license .

and G2R assays. Because of volume constraints, the PHL samples were diluted at least 1:40 prior

to extraction at our lab, resulting in later Ct values for F3L and G2R assays than the Ct values for

- 264 OPXV-E9L assay used by PHL, and complicating quantitative comparison of the assays. The
- 265 qualitative interpretation was 100% concordant.
- In order to quantitatively compare the ability of the three assays to detect MPXV DNA,
- 267 we took 20 MPXV-positive clinical swab specimens in VTM (as detected by MPXV-F3L assay)
- and performed concomitant MPXV-G2R and OPXV-E9L testing on them. In every specimen,
- the MPXV-specific primers gave lower Ct values with averaging Ct differences of 2.4 (range,
- 270 1.3-2.9) and 2.8 (1.6-3.2) lower than OPXV-E9L for MPXV-F3L and MPXV-G2R assays,

271 respectively. In addition, the MPXV-G2R gave a lower Ct value than MPXV-F3L in every

specimen, averaging 0.4 Ct difference (0.1-0.9) (Figure 1B, Supplemental Table 1). This is

273 consistent with two copies of G2R being present in the MPXV genome.



**Figure 1. Specificity of MPXV-F3L and MPXV-G2R assays.** (A) OPXV cross reactivity

analysis of MPXV specific assays by testing MXPV, CPXV, CMLV, and VACV samples, with

- 277 OPXV-E9L used as a positive control. Samples with no detectable MPXV are plotted at Ct of 42.
- 278 (B). Specificity of all three assays with 20 clinical specimens initially positive by MPXV-F3L,
- followed by concomitant testing with MPXV-G2R and MPXV-E9L.
- 280
- 281
- 282 MPXV-F3L, MPXV-G2R and OPXV-E9L assays are not affected by alphaherpesviruses
- 283 Co-infections of MPXV and HSV and VZV have been reported previously (7, 20).
- 284 Therefore, we tested if the presence of HSV or VZV interfered with the detection of MPXV. We
- spiked VR-3270SD into HSV1-, HSV2-, or VZV-positive VTM specimens to a final
- concentration range of 330,000-3,300 MPXV copies/mL (n= 12 herpesvirus positive samples
- total). Contrived MPXV-positive controls with no herpesviruses (n=32) resulted in Cts with no
- significant difference from those MPXV/herpesviruses double positives for all three assays
- 289 (Supplemental Figure 2, Supplemental Table 2, p>0.05, T test).
- 290
- 291 MPXV-F3L, MPXV-G2R, and OPXV-E9L Assays Have Analytic Sensitivity of 3.3 copies per
  292 PCR reaction
- We performed an initial LoD for MPXV-F3L, MPXV-G2R, and OPXV-E9L assays
- using contrived positive specimens containing VR-3270SD at a range of concentrations (33,000-
- 295 33 copies/mL VTM) tested in quadruplicate. For both assays, all four replicates were detected at
- 33,000, 3,300, and 330 copies/mL, while only 2/4 and 3/4 of replicates amplified at 33
- 297 copies/mL with F3L and G2R, respectively. Throughout this range, linearity was excellent
- among positive samples (Supplemental Figure 3), with R<sup>2</sup> values of 0.9990, 0.9986, and 0.9974
- for F3L, G2R, and E9L assays, respectively.

300	Based on these results, we tested twenty additional replicates of contrived positive
301	samples at both 330 copies/mL and 33 copies/mL with F3L and G2R assays. At 330 copies/mL,
302	corresponding to 3.3 copies per PCR reaction, 19/20 and 20/20 replicates were detected for F3L
303	and G2R respectively, with mean Ct values of 34.5 and 36.6 respectively. At 33 copies/mL,
304	corresponding to only 0.3 copies per reaction, 4/20 and 3/20 replicates were detected for F3L and
305	G2R respectively. Therefore, the limit of detection of both F3L and G2R assays is 330
306	copies/mL using standard extraction methods, or 3.3 copies per reaction.
307	To maximize our ability to distinguish between the three assays, an additional LoD study
308	was performed using large volume extraction methods that provided a theoretical 5x
309	concentration of DNA over the standard extraction methods (Supplemental Table 4). This study
310	used both synthetic DNA (VR-3270SD, with equal concentration of all three targets) and high-
311	titer clinical specimen diluted in negative clinical specimens. Similar to the previous LoD study,
312	this was conducted in two stages. First, VR-3270SD was diluted 10-fold in MPXV-negative
313	specimen VTM to final concentrations of 3,300,000-33 copies/mL as well as finer dilutions
314	between 330 and 33 copies/mL, and was tested in quadruplicate. For all three assays, 4/4
315	replicates were detected at 3,300,000-330 and 110 copies/mL dilutions, while only 3/4, 3/4, or
316	1/4 replicate(s) amplified at 66 copies/mL with F3L, G2R, and E9L assays respectively. Second,
317	20 replicates each of both VR-3270SD and the high viral load clinical specimen were tested at
318	330, 110, and 66 copies/mL (copies of F3L for the clinical specimen). For VR-3270SD dilutions,
319	20/20 replicates amplified at 330 copies/mL with all assays; 19/20, 19/20, and 16/20 replicates
320	amplified at 1.1e2 copies/mL with F3L, G2R, and E9L assays respectively; and 12/20, 11/20,
321	and 13/20 replicates amplified at 66 copies/mL with F3L, G2R, and E9L assays respectively. For
322	clinical specimen dilutions at 66 F3L copies/mL by ddPCR and a theoretical 3.3 copies/rxn,

It is made available under a CC-BY 4.0 International license .

323 20/20, 20/20, and 19/20 replicates amplified with F3L, G2R, and E9L assays respectively, with

mean Ct values of 35.0, 33.9, and 36.6 respectively. Therefore, the LoD for each assay using the

325 higher input volume was 110 copies/mL for the F3L and G2R assays and 330 copies/mL VTM

326 for the OPXV-E9L assay based on the ATCC DNA material and 66 copies/mL VTM for each

327 assay based on ddPCR-determined copy number of a viral positive.

328

329 MPXV DNA is detected in diverse specimen types with an LoD of 1000 copies per mL or lower

330 Given the need for testing for MPXV in alternative specimen types in select clinical cases 331 outside of diagnosing monkeypox infection, the UW Virology laboratory also validated the F3L 332 assay in multiple other specimen types. Due to the rarity of many specimen types, we combined 333 our sensitivity and specificity studies with LoD determination, using between 17-24 unique 334 specimens of each type. Presumptive MPXV-negative cerebrospinal fluid, plasma, serum, urine, 335 breastmilk, whole blood, nasopharyngeal/rectal/oral swabs in VTM/UTM, and vaginal/rectal 336 swabs in Aptima tubes, were spiked to a concentration of 1000 copies/mL of VR-3270SD, 337 followed by extraction and qPCR on both spiked and negative samples. The negative percent 338 agreement for all specimen types was 100%. The positive percent agreement for Aptima vaginal 339 and rectal swabs, nasopharyngeal, cerebrospinal fluid, plasma, breastmilk, and whole blood was 340 100%. The F3L assay was positive in 22/23 urine specimens and 21/22 serum specimens, for a 341 positive percent agreement of 95.7% and 95.5% respectively (Figure 2, Supplemental Table 3). 342 Therefore, the F3L LoD for these samples was determined to be 1000 copies/mL.

Once MPXV-positive specimens were available, and specifically for specimen types in which DNA degradation might be a concern (specifically dry swabs, semen, and saliva), we performed our validation using diluted MPXV clinical specimen rather than synthetic DNA. The

It is made available under a CC-BY 4.0 International license .

- high viral load clinical specimen was spiked into semen at 260 copies/mL, and into saliva and
- oral and rectal swabs at 780 copies/mL. Dry swabs were spiked with 810 copies per swab.
- 348 Negative percent agreement of the F3L assay of semen, saliva, rectal, oral, and dry swabs was
- 349 100%. Positive percent agreement was 100% for semen, saliva, and rectal swabs, and 95%
- 350 (19/20) for oral and dry swabs. Therefore, the F3L LoD for semen is 260 copies/mL (5.7 copies
- 351 per PCR reaction), 780 copies/mL (7.8 copies per PCR reaction) for saliva, oral, and rectal

352 swabs, and 810 copies/swab (8.1 copies per PCR reaction) for dry swabs.



353

### 354 Figure 2. Sensitivity of MPXV-F3L With Diverse Specimens.

355 MPXV-F3L Ct values of contrived MPXV positive breastmilk, CSF, dry swabs, nasopharyngeal

356 swabs (NP), plasma, rectal swabs, saliva, semen, urine, vaginal swabs, and whole blood samples

- 357 (n=17-24). Samples with no detectable MPXV are plotted at Ct of 41.
- 358

It is made available under a CC-BY 4.0 International license .

#### 359 **Discussion**

360	Here, we evaluated the sensitivity and specificity of two MPXV-specific primer and
361	probe sets in parallel with an orthopoxvirus assay during the ongoing 2022 MPXV pandemic. By
362	extracting from up to 250 $\mu$ L of specimen, we determined the LoD for MPXV-F3L, MPXV-
363	G2R, and OPXV-E9L assays to be as low as 66 copies/mL, or 3.3 copies per PCR reaction. Our
364	analytical sensitivity compares favorably with a recent evaluation of the PKamp Monkeypox
365	Virus RT-PCR assay, which also uses the F3L gene as its target (21). Furthermore, all three
366	assays did not cross react with HSV or VZV, demonstrating that both assays are highly specific
367	to MPXV even in mixed samples with high HSV/VZV viral titer. We also evaluated the effect of
368	sample matrix on the analytical sensitivity of the MPXV-F3L assay, finding that the assay was
369	robust in fourteen different specimen types.

370

371 Although overall both MPXV-specific assays had very similar performance characteristics, F3L 372 had a slightly lower Ct on average on synthetic positive control material and was present in a 373 core genomic region, leading us to use it as our primary clinical assay for high-volume testing of 374 swabs in VTM (17). In clinical samples, G2R detection was associated with slightly lower Ct 375 values than F3L, likely due to the presence of two copies of the gene in the MPXV ITR regions. 376 However, ITR regions of poxviruses are often subject to genomic rearrangements, especially as 377 they spread to new hosts (22, 23). Reports of rare deletions in the G2R target that affected 378 detection of MPXV DNA led the CDC to issue an advisory on September 2<sup>nd</sup>, 2022, urging 379 caution in the interpretation of negative results returned from the G2R assay if clinical suspicion 380 for MPXV was high (24). To date, no reports of deletions in F3L in MPXV have occurred. 381

- 382 Altogether, we found very similar performance characteristics for the MPXV-F3L, MPXV-G2R,
- 383 and OPXV-E9L assays for the detection of MPXV. Each assay was highly sensitive for MPXV
- 384 DNA, with an LoD around 3 copies per reaction, near the limit of stochasticity. The F3L assay is
- 385 specific for MPXV DNA, and does not cross-react with herpesviruses or other orthopoxviruses.
- 386 This diagnostic will be an important defense for reducing transmission of MPXV during the
- 387 ongoing outbreak.
- 388
- 389 Acknowledgements
- 390 The authors thank our study participants for their time and effort to donate specimens to the
- 391 University of Washington Medical Center. AK is supported by NIH K23 AI153390-01.

It is made available under a CC-BY 4.0 International license .

### 392 References

393

- 1. Ladnyj ID, Ziegler P, Kima E. 1972. A human infection caused by monkeypox virus in
- 395 Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ 46:593–

396 597.

- 2. Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B,
- 398 Labouba I, Gonofio EC, Ouilibona RS, Simo Tchetgna HD, Feher M, Fontanet A, Kazanji
- 399 M, Manuguerra J-C, Hassanin A, Gessain A, Nakoune E. 2021. Genomic history of human
- 400 monkey pox infections in the Central African Republic between 2001 and 2018. 1. Sci Rep
- 401 11:13085.
- 402 3. Thomassen HA, Fuller T, Asefi-Najafabady S, Shiplacoff JAG, Mulembakani PM, Blumberg
- 403 S, Johnston SC, Kisalu NK, Kinkela TL, Fair JN, Wolfe ND, Shongo RL, LeBreton M,
- 404 Meyer H, Wright LL, Muyembe J-J, Buermann W, Okitolonda E, Hensley LE, Lloyd-Smith
- 405 JO, Smith TB, Rimoin AW. 2013. Pathogen-Host Associations and Predicted Range Shifts
- 406 of Human Monkeypox in Response to Climate Change in Central Africa. PLoS ONE407 8:e66071.
- 408 4. Silva NIO, de Oliveira JS, Kroon EG, Trindade G de S, Drumond BP. 2021. Here, There,
- 409 and Everywhere: The Wide Host Range and Geographic Distribution of Zoonotic
- 410 Orthopoxviruses. 1. Viruses 13:43.
- 411 5. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, Doty J, Hughes CM,
- 412 Kabamba J, Malekani J, Bomponda PL, Lokota JI, Balilo MP, Likafi T, Lushima RS, Ilunga
- 413 BK, Nkawa F, Pukuta E, Karhemere S, Tamfum J-JM, Nguete B, Wemakoy EO, McCollum

414	AM Reynolds MG	2016 Extended Human-	to-Human Transm	ission during a	Monkeypox
<b>T1T</b>			lo muman mansin	ission during a	

- 415 Outbreak in the Democratic Republic of the Congo. Emerg Infect Dis 22:1014–1021.
- 416 6. CDC. 2022. Monkeypox in the U.S. Cent Dis Control Prev.
- 417 https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html. Retrieved 17
- 418 August 2022.
- 419 7. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori
- 420 A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M,
- 421 Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V,
- 422 Migaud P, Noe S, Pintado C, Maggi F, Hansen A-BE, Hoffmann C, Lezama JI, Mussini C,
- 423 Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM. 2022.
- 424 Monkeypox Virus Infection in Humans across 16 Countries April–June 2022. N Engl J
  425 Med 0:null.
- 426 8. McCollum AM, Damon IK. 2014. Human monkeypox. Clin Infect Dis Off Publ Infect Dis
  427 Soc Am 58:260–267.
- 428 9. Ježek Z, Szczeniowski M, Paluku KM, Mutombo M. 1987. Human Monkeypox: Clinical
  429 Features of 282 Patients. J Infect Dis 156:293–298.
- 430 10. Monkeypox. https://www.who.int/news-room/fact-sheets/detail/monkeypox. Retrieved 18
  431 August 2022.
- 432 11. Miller MJ. 2022. Severe Monkeypox in Hospitalized Patients United States, August 10–
  433 October 10, 2022. MMWR Morb Mortal Wkly Rep 71.

434	12. Perchetti GA, Nalla AK, Huang M-L, Zhu H, Wei Y, Stensland L, Loprieno MA, Jerome
-----	---

- 435 KR, Greninger AL. 2020. Validation of SARS-CoV-2 detection across multiple specimen
- 436 types. J Clin Virol Off Publ Pan Am Soc Clin Virol 128:104438.
- 437 13. Veintimilla C, Catalán P, Alonso R, de Viedma DG, Pérez-Lago L, Palomo M, Cobos A,
- 438 Aldamiz-Echevarria T, Muñoz P. 2022. The relevance of multiple clinical specimens in the
- diagnosis of monkeypox virus, Spain, June 2022. Euro Surveill Bull Eur Sur Mal Transm
- Eur Commun Dis Bull 27.
- 14. Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. 2010. Real-time PCR assays for the specific
- detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods
  169:223–227.
- 444 15. Maksyutov RA, Gavrilova EV, Shchelkunov SN. 2016. Species-specific differentiation of
  445 variola, monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay. J Virol
  446 Methods 236:215–220.
- 447 16. Li Y, Olson VA, Laue T, Laker MT, Damon IK. 2006. Detection of monkeypox virus with
  448 real-time PCR assays. J Clin Virol Off Publ Pan Am Soc Clin Virol 36:194–203.
- 449 17. Lieberman NAP, Mathias PC, Bradley BT, Greninger AL. 2022. Clinical Performance and
- 450 Trends During the First Two Months of Monkeypox Virus PCR Testing at Two United
- 451 States Reference Labs. preprint. Infectious Diseases (except HIV/AIDS).
- 452 18. Allele-Specific PCR for Determination of IL28B Genotype | Journal of Clinical
- 453 Microbiology. https://journals.asm.org/doi/10.1128/JCM.02084-12?url\_ver=Z39.88-

454	2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed. Retrieved 4 October
455	2022.

- 456 19. Emerson GL, Li Y, Frace MA, Olsen-Rasmussen MA, Khristova ML, Govil D, Sammons
- 457 SA, Regnery RL, Karem KL, Damon IK, Carroll DS. 2009. The Phylogenetics and Ecology
- 458 of the Orthopoxviruses Endemic to North America. PLoS ONE 4:e7666.
- 459 20. Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, Metcalfe MG,
- 460 Likafi T, Lushima RS, Kabamba J, Nguete B, Malekani J, Pukuta E, Karhemere S,
- 461 Muyembe Tamfum J-J, Okitolonda Wemakoy E, Reynolds MG, Schmid DS, McCollum
- 462 AM. 2021. A Tale of Two Viruses: Coinfections of Monkeypox and Varicella Zoster Virus
- in the Democratic Republic of Congo. Am J Trop Med Hyg 104:604–611.
- 464 21. Mondolfi AP, Guerra S, Muñoz M, Luna N, Hernandez MM, Patino LH, Reidy J, Banu R,
- 465 Shrestha P, Liggayu B, Umeaku A, Chen F, Cao L, Patel A, Hanna A, Li S, Look A, Pagani
- 466 N, Albrecht R, Pearl R, Garcia-Sastre A, Bogunovic D, Palacios G, Bonnier L, Cera F,
- 467 Lopez H, Calderon Y, Eiting E, Mullen K, Shin SJ, Lugo LA, Urbina AE, Starks C, Koo T,
- 468 Uychiat P, Look A, van Bakel H, Gonzalez-Reiche A, Betancourt AF, Reich D, Cordon-
- 469 Cardo C, Simon V, Sordillo EM, Ramírez JD. 2022. Evaluation and validation of an RT-
- 470 PCR assay for specific detection of Monkeypox virus (MPXV). J Med Virol
- 471 https://doi.org/10.1002/jmv.28247.
- 472 22. Elde NC, Child SJ, Eickbush MT, Kitzman JO, Rogers KS, Shendure J, Geballe AP, Malik
- 473 HS. 2012. Poxviruses Deploy Genomic Accordions to Adapt Rapidly against Host Antiviral
- 474 Defenses. Cell 150:831–841.

It is made available under a CC-BY 4.0 International license .

- 475 23. Sereewit J, Lieberman NAP, Xie H, Bakhash SAKM, Nunley BE, Chung B, Mills MG,
- 476 Roychoudhury P, Greninger AL. 2022. ORF-Interrupting Mutations in Monkeypox Virus
- 477 Genomes from Washington and Ohio, 2022. 11. Viruses 14:2393.
- 478 24. 2022. Lab Alert: MPXV TNF Receptor Gene Deletion May Lead to False Negative Results
- 479 with Some MPXV Specific LDTs. https://www.cdc.gov/locs/2022/09-02-2022-lab-alert-
- 480 MPXV\_TNF\_Receptor\_Gene\_Deletion\_May\_Lead\_False\_Negative\_Results\_Some\_MPXV
- 481 \_\_Specific\_LDTs.html. Retrieved 21 October 2022.

482